文献速递肝病

熊去氧胆酸治疗的复发性原发性胆汁性胆管炎患者预后评分可预测肝移植后移植物丢失和死亡

Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.
PubMed 文献 · J Hepatol · 2024-05-29

这项国际多中心队列研究纳入332例肝移植后复发性原发性胆汁性胆管炎(rPBC)患者,评估熊去氧胆酸(UDCA)治疗1年时Paris-2、GLOBE和UK-PBC评分对移植物和总体生存的预测价值。中位随访8.7年,52例(16%)发生移植物丢失,103例(31%)死亡;组织学分期、泼尼松使用、ALP×ULN及上述评分均与移植物生存相关,总体生存结果相似。

要点

  • 肝移植后约30%患者发生rPBC,可损害移植物和总体生存。
  • UDCA治疗1年时Paris-2、GLOBE、UK-PBC评分与移植物生存相关。
  • 组织学分期、泼尼松使用和ALP×ULN亦与移植物生存相关。

核心结论

  • 存在疾病活动的rPBC患者(以标准PBC风险评分指示)结局受损,支持以类似移植前PBC的方式治疗复发性疾病。

研究设计与样本

  • 国际多中心队列研究,纳入欧洲、北美和南美28个中心的332例肝移植后rPBC患者。
  • rPBC诊断时中位年龄58.0岁(IQR 53.2-62.6),女性298例(90%)。
  • 在UDCA起始后1年检测血清ALP和胆红素水平,并计算Paris-2、GLOBE和UK-PBC评分。

主要发现

  • rPBC诊断后中位随访8.7年(IQR 4.3-12.9),52例(16%)发生移植物丢失,103例(31%)死亡。
  • UDCA起始1年后多变量分析中,rPBC时组织学分期与移植物生存相关(HR 3.97,95%CI 1.36-11.55,p=0.01)。
  • 泼尼松使用与移植物生存相关(HR 3.18,95%CI 1.04-9.73,p=0.04)。
  • ALP×ULN与移植物生存相关(HR 1.59,95%CI 1.26-2.01,p<0.001)。
  • Paris-2标准与移植物生存相关(HR 4.14,95%CI 1.57-10.92,p=0.004);GLOBE评分相关(HR 2.82,95%CI 1.71-4.66,p<0.001);UK-PBC评分相关(HR 1.06,95%CI 1.03-1.09,p<0.001)。

关键数值与推荐

  • Paris-2标准:HR 4.14(95%CI 1.57-10.92,p=0.004),与移植物生存相关。
  • GLOBE评分:HR 2.82(95%CI 1.71-4.66,p<0.001),与移植物生存相关。
  • UK-PBC评分:HR 1.06(95%CI 1.03-1.09,p<0.001),与移植物生存相关。

临床怎么用

  • 原文结论支持以类似移植前PBC的方式治疗复发性疾病,作者认为对UDCA应答不完全的rPBC患者临床结局更差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recurrent primary biliary cholangitis (rPBC) develops in approximately 30% of patients and negatively impacts graft and overall patient survival after liver transplantation (LT). There is a lack of data regarding the response rate to ursodeoxycholic acid (UDCA) in rPBC. We evaluated a large, international, multi-center cohort to assess the performance of PBC scores in predicting the risk of graft and overall survival after LT in patients with rPBC. METHODS: A total of 332 patients with rPBC after LT were evaluated from 28 centers across Europe, North and South America. The median age at the time of rPBC was 58.0 years [IQR 53.2-62.6], and 298 patients (90%) were female. The biochemical response was measured with serum levels of alkaline phosphatase (ALP) and bilirubin, and Paris-2, GLOBE and UK-PBC scores at 1 year after UDCA initiation. RESULTS: During a median follow-up of 8.7 years [IQR 4.3-12.9] after rPBC diagnosis, 52 patients (16%) had graft loss and 103 (31%) died. After 1 year of UDCA initiation the histological stage at rPBC (hazard ratio [HR] 3.97, 95% CI 1.36-11.55, p = 0.01), use of prednisone (HR 3.18, 95% CI 1.04-9.73, p = 0.04), ALP xULN (HR 1.59, 95% CI 1.26-2.01, p <0.001), Paris-2 criteria (HR 4.14, 95% CI 1.57-10.92, p = 0.004), GLOBE score (HR 2.82, 95% CI 1.71-4.66, p <0.001), and the UK-PBC score (HR 1.06, 95% CI 1.03-1.09, p <0.001) were associated with graft survival in the multivariate analysis. Similar results were observed for overall survival. CONCLUSION: Patients with rPBC and disease activity, as indicated by standard PBC risk scores, have impaired outcomes, supporting efforts to treat recurrent disease in similar ways to pre-transplant PBC. IMPACT AND IMPLICATIONS: One in three people who undergo liver transplantation for primary biliary cholangitis develop recurrent disease in their new liver. Patients with recurrent primary biliary cholangitis and incomplete response to ursodeoxycholic acid, according to conventional prognostic scores, have worse clinical outcomes, with higher risk of graft loss and mortality in similar ways to the disease before liver transplantation. Our results supportsupport efforts to treat recurrent disease in similar ways to pre-transplant primary biliary cholangitis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Montano-Loza AJ, Lytvyak E, Hirschfield G, et al. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation. J Hepatol. 2024. PMID: 38821360. doi:10.1016/j.jhep.2024.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。